3M to sell its drug delivery business to Altaris for $650m
US-based international conglomerate 3M has signed an agreement to divest all of its drug delivery business to an affiliate of Altaris Capital Partners for $650m. Altaris is an
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XUS-based international conglomerate 3M has signed an agreement to divest all of its drug delivery business to an affiliate of Altaris Capital Partners for $650m. Altaris is an
Pfizer has secured the US Food and Drug Administration (FDA) approval for its XELJANZ XR (tofacitinib) for moderately to severely active ulcerative colitis (UC) in adult patients. The
US-based Eli Lilly and Company (Lilly) has started its LIBRETTO-431 clinical trial of LOXO-292 (selpercatinib), for treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC) patients. The pharma firm
Kite, a subsidiary of Gilead, has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for its KTE-X19, intended for relapsed mantle cell
Imperative Care has secured $85m in a Series C financing to advance the launch of its portfolio of advanced neurovascular devices for treating ischemic and hemorrhagic strokes. The
Vertex Pharmaceuticals (Europe) has secured the European Commission (EC) approval for the label extension for KALYDECO (ivacaftor) to include the treatment of cystic fibrosis (CF) in children aged
Sanofi has signed an agreement to acquire Synthorx, a clinical-stage biotechnology company, for an average equity value of around $2.5bn. Sanofi said that the acquisition complements its aim
Merck has signed a definitive agreement to acquire biopharmaceutical firm ArQule for an equity value of around $2.7bn. Under the terms of the agreement, Merck, through its subsidiary,
Janssen Biotech, a company of Johnson & Johnson, has signed an agreement to acquire all rights to bermekimab, an investigational antibody developed by XBiotech, for up to $1.35bn.
US-based biopharmaceutical firm Amgen has secured the US Food and Drug Administration (FDA) approval for AVSOLA (infliximab-axxq), its biosimilar to Remicade (infliximab). Remicade, a chimeric monoclonal antibody biologic,